387 related articles for article (PubMed ID: 23333709)
1. Bottom-up approaches for preparing drug nanocrystals: formulations and factors affecting particle size.
Sinha B; Müller RH; Möschwitzer JP
Int J Pharm; 2013 Aug; 453(1):126-41. PubMed ID: 23333709
[TBL] [Abstract][Full Text] [Related]
2. Drug nanocrystals in the commercial pharmaceutical development process.
Möschwitzer JP
Int J Pharm; 2013 Aug; 453(1):142-56. PubMed ID: 23000841
[TBL] [Abstract][Full Text] [Related]
3. Nanosizing techniques for improving bioavailability of drugs.
Al-Kassas R; Bansal M; Shaw J
J Control Release; 2017 Aug; 260():202-212. PubMed ID: 28603030
[TBL] [Abstract][Full Text] [Related]
4. Nanocrystals: comparison of the size reduction effectiveness of a novel combinative method with conventional top-down approaches.
Salazar J; Ghanem A; Müller RH; Möschwitzer JP
Eur J Pharm Biopharm; 2012 May; 81(1):82-90. PubMed ID: 22233547
[TBL] [Abstract][Full Text] [Related]
5. Application of precipitation methods for the production of water-insoluble drug nanocrystals: production techniques and stability of nanocrystals.
Xia D; Gan Y; Cui F
Curr Pharm Des; 2014; 20(3):408-35. PubMed ID: 23651396
[TBL] [Abstract][Full Text] [Related]
6. Supercritical carbon dioxide-based technologies for the production of drug nanoparticles/nanocrystals - A comprehensive review.
Padrela L; Rodrigues MA; Duarte A; Dias AMA; Braga MEM; de Sousa HC
Adv Drug Deliv Rev; 2018 Jun; 131():22-78. PubMed ID: 30026127
[TBL] [Abstract][Full Text] [Related]
7. Systematic investigation of the cavi-precipitation process for the production of ibuprofen nanocrystals.
Sinha B; Müller RH; Möschwitzer JP
Int J Pharm; 2013 Dec; 458(2):315-23. PubMed ID: 24148667
[TBL] [Abstract][Full Text] [Related]
8. Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives.
Shegokar R; Müller RH
Int J Pharm; 2010 Oct; 399(1-2):129-39. PubMed ID: 20674732
[TBL] [Abstract][Full Text] [Related]
9. Production of pure drug nanocrystals and nano co-crystals by confinement methods.
Fontana F; Figueiredo P; Zhang P; Hirvonen JT; Liu D; Santos HA
Adv Drug Deliv Rev; 2018 Jun; 131():3-21. PubMed ID: 29738786
[TBL] [Abstract][Full Text] [Related]
10. Enhancing the solubility and bioavailability of poorly water-soluble drugs using supercritical antisolvent (SAS) process.
Abuzar SM; Hyun SM; Kim JH; Park HJ; Kim MS; Park JS; Hwang SJ
Int J Pharm; 2018 Mar; 538(1-2):1-13. PubMed ID: 29278733
[TBL] [Abstract][Full Text] [Related]
11. A novel high-pressure precipitation tandem homogenization technology for drug nanocrystals production - a case study with ursodeoxycholic acid.
Li Y; Wang Y; Yue PF; Hu PY; Wu ZF; Yang M; Yuan HL
Pharm Dev Technol; 2014 Sep; 19(6):662-70. PubMed ID: 23869484
[TBL] [Abstract][Full Text] [Related]
12. Pharmaceutical and pharmacokinetic characteristics of different types of fenofibrate nanocrystals prepared by different bottom-up approaches.
Zhang H; Meng Y; Wang X; Dai W; Wang X; Zhang Q
Drug Deliv; 2014 Dec; 21(8):588-94. PubMed ID: 24320001
[TBL] [Abstract][Full Text] [Related]
13. Nanoparticles in the pharmaceutical industry and the use of supercritical fluid technologies for nanoparticle production.
Sheth P; Sandhu H; Singhal D; Malick W; Shah N; Kislalioglu MS
Curr Drug Deliv; 2012 May; 9(3):269-84. PubMed ID: 22283656
[TBL] [Abstract][Full Text] [Related]
14. Performance comparison of two novel combinative particle-size-reduction technologies.
Salazar J; Müller RH; Möschwitzer JP
J Pharm Sci; 2013 May; 102(5):1636-49. PubMed ID: 23436640
[TBL] [Abstract][Full Text] [Related]
15. Pharmaceutical nanocrystals: production by wet milling and applications.
Malamatari M; Taylor KMG; Malamataris S; Douroumis D; Kachrimanis K
Drug Discov Today; 2018 Mar; 23(3):534-547. PubMed ID: 29326082
[TBL] [Abstract][Full Text] [Related]
16. Nanocrystal Based Drug Delivery System: Conventional and Current Scenario.
Thakkar S; Shah V; Misra M; Kalia K
Recent Pat Nanotechnol; 2017 Jul; 11(2):130-145. PubMed ID: 27758683
[TBL] [Abstract][Full Text] [Related]
17. Engineered nanocrystal technology: in-vivo fate, targeting and applications in drug delivery.
Pawar VK; Singh Y; Meher JG; Gupta S; Chourasia MK
J Control Release; 2014 Jun; 183():51-66. PubMed ID: 24667572
[TBL] [Abstract][Full Text] [Related]
18. Precipitation-lyophilization-homogenization (PLH) for preparation of clarithromycin nanocrystals: influencing factors on physicochemical properties and stability.
Morakul B; Suksiriworapong J; Leanpolchareanchai J; Junyaprasert VB
Int J Pharm; 2013 Nov; 457(1):187-96. PubMed ID: 24076396
[TBL] [Abstract][Full Text] [Related]
19. Production of nanosuspensions as a tool to improve drug bioavailability: focus on topical delivery.
Lai F; Schlich M; Pireddu R; Corrias F; Fadda AM; Sinico C
Curr Pharm Des; 2015; 21(42):6089-103. PubMed ID: 26503149
[TBL] [Abstract][Full Text] [Related]
20. Drug nanocrystals - Versatile option for formulation of poorly soluble materials.
Peltonen L; Hirvonen J
Int J Pharm; 2018 Feb; 537(1-2):73-83. PubMed ID: 29262301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
